Radioimmunotherapy in follicular lymphoma: Some like it hot...

Transfusion and Apheresis Science

Volumn 44, Issue 2, 2011, Pages 173-178

  Kersten, Marie José ^a  

^a ACADEMIC MEDICAL CENTER   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

CYCLOPHOSPHAMIDE; DOXORUBICIN; ETOPOSIDE; FLUDARABINE; IBRITUMOMAB TIUXETAN; MITOXANTRONE; PREDNISOLONE; RITUXIMAB; TOSITUMOMAB I 131; VINCRISTINE;

ARTICLE; CANCER COMBINATION CHEMOTHERAPY; CANCER IMMUNOTHERAPY; CANCER RADIOTHERAPY; DRUG EFFICACY; DRUG MEGADOSE; DRUG SAFETY; FOLLICULAR LYMPHOMA; HUMAN; MONOTHERAPY; PROGRESSION FREE SURVIVAL; RADIATION DOSE; TREATMENT RESPONSE;

ALGORITHMS; ANIMALS; ANTIBODIES, MONOCLONAL; ANTIGENS, CD20; DISEASE-FREE SURVIVAL; HUMANS; LYMPHOMA, FOLLICULAR; MICE; RADIOIMMUNOTHERAPY; REMISSION INDUCTION; SALVAGE THERAPY; STEM CELLS; TREATMENT OUTCOME;

EID: 79952630020     PISSN: 14730502     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.transci.2011.01.015     Document Type: Article

References (36)

1. Jemal A., Siegel R., Ward E., et al. Cancer statistics, 2009. CA Cancer J Clin 2009, 59:225-249.
2. Friedberg J.W., Taylor M.D., Cerhan J.R., et al. Follicular lymphoma in the United States: first report of the National LymphoCare Study. J Clin Oncol 2009, 27:1202-1208.
3. Schulz H., Bohlius J.F., Trelle S., et al. Immunochemotherapy with rituximab and overall survival in patients with indolent or mantle cell lymphoma: a systematic review and meta-analysis. J Natl Cancer Inst 2007, 99:706-714.
4. DeNardo S.J., DeNardo G.L., O'Grady L.F., et al. Pilot studies of radioimmunotherapy of B cell lymphoma and leukemia using I-131-Lm1 monoclonal antibody. Antibody Immunoconjugates Radiopharmaceuticals 1988, 1:17-33.
5. Kaminski M.S., Zelenetz A.D., Press O.W., et al. Pivotal study of iodine-131-tositumomab for chemotherapy-refractory low-grade or transformed low-grade B-cell non-Hodgkin's lymphomas. J Clin Oncol 2001, 19:3918-3928.
6. Fisher R.I., Kaminski M.S., Wahl R.L., et al. Tositumomab and iodine-131-tositumomab produces durable complete remissions in a subset of heavily pretreated patients with low-grade and transformed non-Hodgkin's lymphoma. J Clin Oncol 2005, 30:7565-7573.
7. Horning S.J., Younes A., Jain V., et al. Efficacy and safety of tositumomab and iodine-131-tositumomab (Bexxar) in B-cell lymphoma, progressive after rituximab. J Clin Oncol 2005, 23:712-719.
8. Davis T.A., Kaminski M.S., Leonard J.P., et al. The radioisotope contributes significantly to the activity of radioimmunotherapy. Clin Cancer Res 2004, 23:7792-7798.
9. Kaminski M.S., Tuck M., Estes J., et al. 131-Tositumomab therapy as initial treatment for follicular lymphoma. N Engl J Med 2005, 352:441-449.
10. Witzig T.E., Flinn I.W., Gordon L.I., et al. Treatment with ibritumomab tiuxetan radioimmunotherapy in patients with rituximab-refractory follicular non-Hodgkin's lymphoma. J Clin Oncol 2002, 20:3262-3269.
11. Witzig T.E., Gordon L.I., Cabanillas F., et al. Randomized controlled trial of yttrium-90-labeled ibritumomab tiuxetan radioimmunotherapy versus rituximab immunotherapy for patients with relapsed or refractory low-grade, follicular, or transformed B-cell non-Hodgkin's lymphoma. J Clin Oncol 2002, 20:2453-2463.
12. Witzig T.E., Molina A., Gordon L.I., et al. Long-term responses in patients with recurring or refractory B-cell non-Hodgkin lymphoma treated with yttrium-90 ibritumomab tiuxetan. Cancer 2007, 109:1804-1810.
13. Press O.W., Unger J.M., Braziel R.M., et al. Phase II trial of CHOP chemotherapy followed by 131I-tositumomab for previously untreated follicular non-Hodgkin's lymphoma: 5-year followup of Southwest Oncology Group Protocol S9911. J Clin Oncol 2006, 24:4143-4149.
14. Link B.K., Martin P., Kaminski M.S., et al. Cyclophosphamide, vincristine, and prednisone followed by tositumomab and iodine-131-tositumomab in patients with untreated low-grade follicular lymphoma: eight-year follow-up of a multicenter phase II study. J Clin Oncol 2010, 20:3035-3041.
15. Leonard J.P., Coleman M., Kostakoglu L., et al. Abbreviated chemotherapy with fludarabine followed by tositumomab and iodine I 131 tositumomab for untreated follicular lymphoma. J Clin Oncol 2005, 23:5696-5704.
16. Zinzani P.L., Tani M., Pulsoni A., Gobbi M., et al. Fludarabine and mitoxantrone followed by yttrium-90 ibritumomab tiuxetan in previously untreated patients with follicular non-Hodgkin lymphoma trial: a phase II non-randomised trial (FLUMIZ). Lancet Oncol 2008, 9:352-358.
17. Morschhauser F., Radford J., van Hoof A., et al. Phase III trial of consolidation therapy with yttrium-90-ibritumomab tiuxetan compared with no additional therapy after first remission in advanced follicular lymphoma. J Clin Oncol 2008, 26:5156-5164.
18. Jacobs S.A., Swerdlow S.H., Kant J., et al. Phase II trial of short-course CHOP-R followed by 90Y-ibritumomab tiuxetan and extended rituximab in previously untreated follicular lymphoma. Clin Cancer Res 2008, 14:7099-7794.
19. Hainsworth J.D., Spigel D.R., Markus T.M., et al. Rituximab plus short-duration chemotherapy followed by yttrium-90 ibritumomab tiuxetan as first-line treatment for patients with follicular non-Hodgkin lymphoma: a phase II trial of the Sarah Cannon Oncology Research Consortium. Clin Lymphoma Myeloma 2009, 9:223-228.
20. Press O.W., Eary J.F., Appelbauw F.R., et al. Radiolabeled-antibody therapy of B-cell lymphoma with autologous bone marrow support. N Engl J Med 1993, 329:1219-1224.
21. Liu S.Y., Eary J.F., Petersdorf S.H., et al. Follow-up of relapsed B-cell lymphoma patients treated with iodine-131-labed anti-CD20 antibody and autologous stem cell rescue. J Clin Oncol 1998, 16:3270-3278.
22. Gopal A.K., Gooley T.A., Maloney D.G., et al. High-dose radioimmunotherapy versus conventional high-dose therapy and autologous hematopoietic stem cell transplantation for relapsed follicular non-Hodgkin lymphoma: a multivariable cohort analysis. Blood 2003, 102:2351-2357.
23. Devizzi L., Guidetti A., Tarella C., et al. High dose yttrium-90-ibritumomab tiuxetan with tandem stem-cell reinfusion: an outpatient preparative regimen for autologous hematopoietic cell transplantation. J Clin Oncol 2008, 26:5175-5182.
24. Press O.W., Eary J.F., Gooley T., et al. A phase I/II trial of iodine-131-tositumomab (anti-CD20), etoposide, cyclophosphamide, and autologous stem cell transplantation for relapsed B-cell lymphomas. Blood 2000, 96:2934-2942.
25. Vose J.M., Bierman P.J., Enke C., et al. Phase I trial of Iodine-131 tositumomab with high-dose chemotherapy and autologous stem-cell transplantation for relapsed non-Hodgkin's lymphoma. J Clin Oncol 2005, 23:461-467.
26. Nademanee A., Forman S., Molina A., et al. A phase 1/2 trial of high-dose yttrium-90 ibritumomab tiuxetan in combination with high-dose etoposide and cyclophosphamide followed by autologous stem cell transplantation in patients with poor-risk or relapsed non-Hodgkin lymphoma. Blood 2005, 106:2896-2902.
27. Winter J.N., Inwards D.J., Spies S., et al. Yttrium-90 ibritumomab tiuxetan doses calculated to deliver up to 15 Gy to critical organs may be safely combined with high-dose BEAM and autologous stem cell transplantation in relapsed or refractory B-cell non-Hodgkin's lymphoma. J Clin Oncol 2009, 27:1653-1659.
28. Gisselbrecht C., Decaudin D., Mounier N., et al. 90-Yttrium ibritumomab tiuxetan (Zevalin) combined with BEAM (Z-BEAM) conditioning regimen plus autologous stem cell transplantation in relapsed or refractory follicular lymphoma. GELA phase II study. Blood 2007, 110:22. [ASH annual meeting abstracts].
29. Palanca-Wessels M.C., Press O.W. Improving the efficacy of radioimmunotherapy for non-Hodgkin lymphomas. Cancer 2010, 116:1126-1133.
30. Pagel J.M., Orgun N., Hamlin D.K., et al. A comparative analysis of conventional and pretargeted radioimmunotherapy of B-cell lymphomas by targeting CD20, CD22, and HLA-DR singly and in combinations. Blood 2009, 113:4903-4913.
31. Goldenberg D.M., Sharkey R.M., Paganelli G., et al. Antibody pretargeting advances cancer radioimmunodetection and radioimmunotherapy. J Clin Oncol 2006, 24:823-834.
32. Czuczman M.S., Emmanoulides C., Darif M., et al. Treatment-related myelodysplastic syndrome and acute myelogenous leukemia in patients treated with ibritumomab tiuxetan radioimmunotherapy. J Clin Oncol 2007, 25:4285-4292.
33. Bennett J.M., Kaminski M.S., Leonard J.P., et al. Assessment of treatment-related myelodysplastic syndromes and acute myelogenous leukemia in patients with non-Hodgkin lymphoma treated with tositumomab and iodine 131 tositumomab. Blood 2005, 105:4576-4582.
34. Ansell S.M., Ristow K.M., Habermann T.M., et al. Subsequent chemotherapy regimens are well tolerated after radioimmunotherapy with yttrium-90 ibritumomab tiuxetan for non-Hodgkin's lymphoma. J Clin Oncol 2002, 20:3885-3890.
35. Dosik A.D., Coleman M., Kostakoglu L., et al. Subsequent therapy can be administered after tositumomab and iodine-131 tositumomab for non-Hodgkin's lymphoma. Cancer 2006, 106:616-622.
36. Kaminski M.S., Radford J.A., Gregory S.A., et al. Retreatment with I-131 tositumomab in patients with non-Hodgkin's lymphoma who had previously responded to I-131 tositumomab. J Clin Oncol 2005, 23:7985-7993.